Discovery of a New Action of Macrolide Drugs: Suppresses Proinflammatory Components Released by Streptococcus pneumoniae
May 23, 2023
A research group led by Associate Professor DOMON Hisanori and Professor TERAO Yutaka of the Division of Microbiology and Infectious Diseases, Graduate School of Medical and Dental Sciences, Niigata University discovered that azithromycin and erythromycin, macrolides drugs1, prevent exacerbation of inflammation by suppressing the production of inflammation inducers released by Streptococcus pneumoniae. The research was published in the online version of the US scientific journal Microbiology Spectrum on May 16, 2023.
Research results
- Streptococcus pneumoniae releases proinflammatory components such as peptidoglycan and lipoproteins, causing inflammation in the body.
- This research discovered that macrolides suppress the production of these proinflammatory components .
- The research may lead to the development of a treatment for pneumonia that targets bacterial proinflammatory components.
[Glossary]
1. An antibacterial agent that suppresses protein synthesis in bacteria.
Publication Details
Journal: Microbiology Spectrum
Title: Macrolides decrease the proinflammatory activity of macrolide-resistant Streptococcus pneumoniae
Authors: Hisanori Domon, Satoru Hirayama, Toshihito Isono, Karin Sasagawa, Fumio Takizawa, Tomoki Maekawa, Katsunori Yanagihara, Yutaka Terao
doi: 10.1128/spectrum.00148-23
More News
-
Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform
Research results
-
Hidden Acid Imbalance in Kidney Disease Raises Red Flags
Research results
-
Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer's disease neuroimaging initiative cohort
Research results
-
From surface to depth: 3D imaging traces vascular amyloid spread in the human brain
Research results